vs
COMSCORE, INC.（SCOR）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是COMSCORE, INC.的1.5倍（$139.1M vs $93.5M），VERACYTE, INC.净利率更高（20.6% vs 3.2%，领先17.4%），VERACYTE, INC.同比增速更快（21.5% vs -1.5%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 3.8%）
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
SCOR vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.5倍
$93.5M
营收增速更快
VCYT
高出23.0%
-1.5%
净利率更高
VCYT
高出17.4%
3.2%
两年增速更快
VCYT
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $93.5M | $139.1M |
| 净利润 | $3.0M | $28.7M |
| 毛利率 | 41.0% | 72.7% |
| 营业利润率 | 7.0% | 16.3% |
| 净利率 | 3.2% | 20.6% |
| 营收同比 | -1.5% | 21.5% |
| 净利润同比 | -3.7% | — |
| 每股收益（稀释后） | $9.50 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCORVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $93.5M | $140.6M | ||
| Q3 25 | $88.9M | $131.9M | ||
| Q2 25 | $89.4M | $130.2M | ||
| Q1 25 | $85.7M | $114.5M | ||
| Q4 24 | $94.9M | $118.6M | ||
| Q3 24 | $88.5M | $115.9M | ||
| Q2 24 | $85.8M | $114.4M |
净利润SCORVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $3.0M | $41.1M | ||
| Q3 25 | $453.0K | $19.1M | ||
| Q2 25 | $-9.5M | $-980.0K | ||
| Q1 25 | $-4.0M | $7.0M | ||
| Q4 24 | $3.1M | $5.1M | ||
| Q3 24 | $-60.6M | $15.2M | ||
| Q2 24 | $-1.7M | $5.7M |
毛利率SCORVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 41.0% | 72.5% | ||
| Q3 25 | 40.6% | 69.2% | ||
| Q2 25 | 40.6% | 69.0% | ||
| Q1 25 | 39.6% | 69.5% | ||
| Q4 24 | 42.4% | 66.4% | ||
| Q3 24 | 41.2% | 68.2% | ||
| Q2 24 | 39.5% | 68.1% |
营业利润率SCORVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 7.0% | 26.4% | ||
| Q3 25 | 1.9% | 17.4% | ||
| Q2 25 | -1.9% | -4.0% | ||
| Q1 25 | -2.4% | 2.5% | ||
| Q4 24 | 4.1% | 3.5% | ||
| Q3 24 | -67.4% | 10.4% | ||
| Q2 24 | -2.2% | 4.0% |
净利率SCORVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 3.2% | 29.3% | ||
| Q3 25 | 0.5% | 14.5% | ||
| Q2 25 | -10.6% | -0.8% | ||
| Q1 25 | -4.7% | 6.2% | ||
| Q4 24 | 3.3% | 4.3% | ||
| Q3 24 | -68.5% | 13.1% | ||
| Q2 24 | -2.0% | 5.0% |
每股收益（稀释后）SCORVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $9.50 | $0.50 | ||
| Q3 25 | $-0.86 | $0.24 | ||
| Q2 25 | $-2.73 | $-0.01 | ||
| Q1 25 | $-1.66 | $0.09 | ||
| Q4 24 | $-0.47 | $0.07 | ||
| Q3 24 | $-12.79 | $0.19 | ||
| Q2 24 | $-1.19 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.6M | $439.1M |
| 总债务越低越好 | $41.5M | — |
| 股东权益账面价值 | $111.4M | $1.3B |
| 总资产 | $407.7M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资SCORVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $23.6M | $362.6M | ||
| Q3 25 | $26.7M | $315.6M | ||
| Q2 25 | $26.0M | $219.5M | ||
| Q1 25 | $31.0M | $186.1M | ||
| Q4 24 | $29.9M | $239.1M | ||
| Q3 24 | $20.0M | $274.1M | ||
| Q2 24 | $14.7M | $235.9M |
总债务SCORVCYT
| Q1 26 | — | — | ||
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益SCORVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $111.4M | $1.3B | ||
| Q3 25 | $-26.3M | $1.3B | ||
| Q2 25 | $-21.7M | $1.2B | ||
| Q1 25 | $-13.5M | $1.2B | ||
| Q4 24 | $-8.3M | $1.2B | ||
| Q3 24 | $-2.7M | $1.2B | ||
| Q2 24 | $45.8M | $1.1B |
总资产SCORVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $407.7M | $1.4B | ||
| Q3 25 | $406.9M | $1.4B | ||
| Q2 25 | $415.9M | $1.3B | ||
| Q1 25 | $421.5M | $1.3B | ||
| Q4 24 | $430.2M | $1.3B | ||
| Q3 24 | $412.5M | $1.3B | ||
| Q2 24 | $474.1M | $1.2B |
负债/权益比SCORVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $2.9M | — |
| 自由现金流率自由现金流/营收 | 3.1% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | 1.07× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $21.8M | — |
8季度趋势，按日历期对齐
经营现金流SCORVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $3.2M | $52.6M | ||
| Q3 25 | $9.5M | $44.8M | ||
| Q2 25 | $932.0K | $33.6M | ||
| Q1 25 | $9.1M | $5.4M | ||
| Q4 24 | $-10.0M | $24.5M | ||
| Q3 24 | $12.5M | $30.0M | ||
| Q2 24 | $8.7M | $29.6M |
自由现金流SCORVCYT
| Q1 26 | — | — | ||
| Q4 25 | $2.9M | $48.8M | ||
| Q3 25 | $9.4M | $42.0M | ||
| Q2 25 | $787.0K | $32.3M | ||
| Q1 25 | $8.7M | $3.5M | ||
| Q4 24 | $-10.3M | $20.4M | ||
| Q3 24 | $12.4M | $27.7M | ||
| Q2 24 | $8.5M | $26.8M |
自由现金流率SCORVCYT
| Q1 26 | — | — | ||
| Q4 25 | 3.1% | 34.7% | ||
| Q3 25 | 10.5% | 31.8% | ||
| Q2 25 | 0.9% | 24.8% | ||
| Q1 25 | 10.1% | 3.1% | ||
| Q4 24 | -10.8% | 17.2% | ||
| Q3 24 | 14.0% | 23.9% | ||
| Q2 24 | 10.0% | 23.4% |
资本支出强度SCORVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 2.7% | ||
| Q3 25 | 0.1% | 2.1% | ||
| Q2 25 | 0.2% | 1.0% | ||
| Q1 25 | 0.4% | 1.6% | ||
| Q4 24 | 0.2% | 3.5% | ||
| Q3 24 | 0.1% | 1.9% | ||
| Q2 24 | 0.2% | 2.4% |
现金转化率SCORVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 1.07× | 1.28× | ||
| Q3 25 | 20.96× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | -3.19× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
